Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roselabs Bioscience and Roselabs Polymers have invested a sum of $68.29m to establish the pre-filled syringe (PFS) manufacturing plant, which has already received approval from the World Health Organization-Good Manufacturing Practice (WHO-GMP).
Subscribe to our email newsletter
Commenting on further clearances, Roselabs Biosciences director Zameer Agarwal was quoted by The Hindu as saying that Roselabs is awaiting regulatory approvals from 35-40 countries.
A drug delivery system in regulated markets, PFS seeks to deliver assured sterility, safety, convenience, greater accuracy, minimal over-filling, low medical waste, and eliminate accidental needle stick injuries, he added.
At the facility, Roselabs seeks to manufacture empty glass and polymer syringes, contract manufacturing, development of any formulation in PFS, and of customised drug delivery system and marketing formulations under its own brand name.
The company has commenced production six months ago, Agarwal said.